Patients With Systemic Sclerosis Present Increased Dna Damage Differentially Associated With Dna Repair Gene Polymorphisms

Objective. Patients with systemic sclerosis (SSc) exhibit increased toxicity when exposed to genotoxic agents. In our study, we evaluated DNA damage and polymorphic sites in 2 DNA repair genes (XRCC1 Arg399Gln and XRCC4 Ile401Thr) in patients with SSc. Methods. A total of 177 patients were studied for DNA repair gene polymorphisms. Fifty-six of them were also evaluated for DNA damage in peripheral blood cells using the comet assay. Results. Compared to controls, the patients as a whole or stratified into major clinical variants (limited or diffuse skin involvement), irrespective of the underlying treatment schedule, exhibited increased DNA damage. XRCC1 (rs: 25487) and XRCC4 (rs: 28360135) allele and genotype frequencies observed in patients with SSc were not significantly different from those observed in controls; however, the XRCC1 Arg399Gln allele was associated with increased DNA damage only in healthy controls and the XRCC4 Ile401Thr allele was associated with increased DNA damage in both patients and controls. Further, the XRCC1 Arg399Gln allele was associated with the presence of antinuclear antibody and anticentromere antibody. No association was observed between these DNA repair gene polymorphic sites and clinical features of patients with SSc. Conclusion. These results corroborate the presence of genomic instability in SSc peripheral blood cells, as evaluated by increased DNA damage, and show that polymorphic sites of the XRCC1 and XRCC4 DNA repair genes may differentially influence DNA damage and the development of autoantibodies. Copyright © 2014. All rights reserved.413458465Domsic, R.T., Medsger Jr., T.A., Connective tissue diseases: Predicting death in SSc: Planning and cooperation are needed (2011) Nat Rev Rheumatol, 7, pp. 628-630Van Bon, L., Cossu, M., Radstake, T.R., An update on an immune system that goes awry in systemic sclerosis (2011) Curr Opin Rheumatol, 23, pp. 505-510Abraham, D.J., Varga, J., Scleroderma: From cell and molecular mechanisms to disease models (2005) Trends in Immunology, 26 (11), pp. 587-595. , DOI 10.1016/j.it.2005.09.004, PII S1471490605002395, Autoimmunity Special IssueAbraham, D., Distler, O., How does endothelial cell injury start? The role of endothelin in systemic sclerosis (2007) Arthritis Res Ther, 9 (SUPPL. 2), pp. S2Evans, M.D., Cooke, M.S., Oxidative damage to DNA in non-malignant disease: Biomarker or biohazard? (2006) Genome Dyn, 1, pp. 53-66Tsuruta, D., Ohzono, A., Ishii, N., Ono, F., Hamada, T., Dainichi, T., Overlap syndrome comprised of systemic sclerosis and systemic lupus erythematosus associated with spinocerebellar ataxia type 6 and MALT lymphoma (2013) Eur J Dermatol, 23, p. 117Lee, K.-J., Dong, X., Wang, J., Takeda, Y., Dynan, W.S., Identification of human autoantibodies to the DNA ligase IV/XRCC4 complex and mapping of an autoimmune epitope to a potential regulatory region (2002) Journal of Immunology, 169 (6), pp. 3413-3421Lo, S.F., Wan, L., Huang, C.M., Lin, H.C., Chen, S.Y., Liu, S.C., Genetic polymorphisms of the DNA repair gene UNG are associated with the susceptibility of rheumatoid arthritis (2012) Rheumatol Int, 32, pp. 3723-3727Bassi, C., Xavier, D.J., Palomino, G., Nicolucci, P., Soares, C., Sakamoto-Hojo, E., Efficiency of the DNA repair and polymorphisms of the XRCC1, XRCC3 and XRCC4 DNA repair genes in systemic lupus erythematosus (2008) Lupus, 17, pp. 988-995Housset, E., Emerit, I., Baulon, A., De Grouchy, J., Anomalies chromosomiques dans la sclérodermie géné ralisée. Une étude de 6 patients (French). Chromosome anomalies in generalized scleroderma. A study of 6 patients (1969) C R Acad Sci Hebd Seances Acad Sci D, 269, pp. 413-416Artlett, C.M., Black, C.M., Briggs, D.C., Stevens, C.O., Welsh, K.I., Telomere reduction in scleroderma patients: A possible cause for chromosomal instability (1996) Br J Rheumatol, 35, pp. 732-737Majone, F., Zamboni, D., Cozzi, F., Montaldi, A., Grypiotis, P., Luisetto, R., Favaro, M., Ruffatti, A., Unstabilized DNA breaks in lymphocytes of patients with systemic sclerosis (2006) European Journal of Dermatology, 16 (3), pp. 258-261Martins, E.P., Fuzzi, H.T., Kayser, C., Alarcon, R.T., Rocha, M.G., Chauffaille, M.L., Increased chromosome damage in systemic sclerosis skin fibroblasts (2010) Scand J Rheumatol, 39, pp. 398-401Fenech, M., The cytokinesis-block micronucleus technique: A detailed description of the method and its application to genotoxicity studies in human populations (1993) Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 285 (1), pp. 35-44. , DOI 10.1016/0027-5107(93)90049-LPorciello, G., Scarpato, R., Storino, F., Migliore, L., Ferri, C., Cagetti, F., Morozzi, G., Galeazzi, M., Chromosome aberrations in Raynaud's phenomenon (2004) European Journal of Dermatology, 14 (5), pp. 327-331Burt, R.K., Kallunian, K., Patel, D., Thomas, J., Yeager, A., Traynor, A., Heipe, F., Snowden, J., The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens: Concerns over the use of total-body irradiation in systemic sclerosis (2004) Bone Marrow Transplantation, 34 (9), pp. 745-751. , DOI 10.1038/sj.bmt.1704671Masson, M., Niedergang, C., Schreiber, V., Muller, S., Menissier-De, M.J., De Murcia, G., XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage (1998) Molecular and Cellular Biology, 18 (6), pp. 3563-3571Caldecott, K.W., Aoufouchi, S., Johnson, P., Shall, S., XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular 'nick-sensor' in vitro (1996) Nucleic Acids Research, 24 (22), pp. 4387-4394. , DOI 10.1093/nar/24.22.4387Thompson, L.H., West, M.G., XRCC1 keeps DNA from getting stranded (2000) Mutation Research - DNA Repair, 459 (1), pp. 1-18. , DOI 10.1016/S0921-8777(99)00058-0, PII S0921877799000580Duarte, M.C., Colombo, J., Rossit, A.R.B., Caetano, A., Borim, A.A., Wornrath, D., Silva, A.E., Polymorphisms of DNA repair genes XRCC1 and XRCC3, interaction with environmental exposure and risk of chronic gastritis and grastic cancer (2005) World Journal of Gastroenterology, 11 (42), pp. 6593-6600Zhang, H., Li, W., Franklin, M.J., Dudek, A.Z., Polymorphisms in DNA repair gene XRCC1 and skin cancer risk: A meta-analysis (2011) Anticancer Res, 31, pp. 3945-3952Sturgis, E.M., Castillo, E.J., Li, L., Zheng, R., Eicher, S.A., Clayman, G.L., Strom, S.S., Wei, Q., Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck (1999) Carcinogenesis, 20 (11), pp. 2125-2129. , DOI 10.1093/carcin/20.11.2125Abdel-Rahman, S.Z., Soliman, A.S., Bondy, M.L., Omar, S., El-Badawy, S.A., Khaled, H.M., Inheritance of the 194Trp and the 399Gln variant alleles of the DNA repair gene XRCC1 are associated with increased risk of early-onset colorectal carcinoma in Egypt (2000) Cancer Lett, 159, pp. 79-86Shen, H., Xu, Y., Qian, Y., Yu, R., Qin, Y., Zhou, L., Polymorphisms of the DNA repair gene XRCC1 and risk of gastric cancer in a Chinese population (2000) Int J Cancer, 88, pp. 601-606Yu, C.L., Huang, M.H., Tsai, C.Y., Tsai, Y.Y., Tsai, S.T., Sun, K.H., The effect of human polyclonal anti-dsDNA autoantibodies on apoptotic gene expression in cultured rat glomerular mesangial cells (1998) Scand J Rheumatol, 27, pp. 54-60Duell, E.J., Millikan, R.C., Pittman, G.S., Winkel, S., Lunn, R.M., Tse, C.-K.J., Eaton, A., Bell, D.A., Polymorphisms in the DNA repair gene XRCC1 and breast cancer (2001) Cancer Epidemiology Biomarkers and Prevention, 10 (3), pp. 217-222Zhou, W., Liu, G., Miller, D.P., Thurston, S.W., Xu, L.L., Wain, J.C., Lynch, T.J., Christiani, D.C., Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk (2003) Cancer Epidemiology Biomarkers and Prevention, 12 (4), pp. 359-365Lees-Miller, S.P., Meek, K., Repair of DNA double strand breaks by non-homologous end joining (2003) Biochimie, 85 (11), pp. 1161-1173. , DOI 10.1016/j.biochi.2003.10.011Ford, B.N., Ruttan, C.C., Kyle, V.L., Brackley, M.E., Glickman, B.W., Identification of single nucleotide polymorphisms in human DNA repair genes (2000) Carcinogenesis, 21, pp. 1977-1981Burma, S., Chen, B.P.C., Chen, D.J., Role of non-homologous end joining (NHEJ) in maintaining genomic integrity (2006) DNA Repair, 5 (9-10), pp. 1042-1048. , DOI 10.1016/j.dnarep.2006.05.026, PII S1568786406001650, Mechanisms of Chromosomal TranslocationsMasi, A.T., Rodnan, G.P., Medsger, T.A., Preliminary criteria for the classification of systemic sclerosis (scleroderma) (1980) Arthritis and Rheumatism, 23 (5), pp. 581-590Carwile L.Roy, E., Black, C., Fleischmajer, R., Jablonska, S., Krieg, T., Medsger Jr., T.A., Wollheim, F., Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis (1988) Journal of Rheumatology, 15 (2), pp. 202-205Miller, S.A., Dykes, D.D., Polesky, H.F., A simple salting out procedure for extracting DNA from human nucleated cells (1988) Nucleic Acids Res, 16, p. 1215Relton, C.L., Daniel, C.P., Hammal, D.M., Parker, L., Tawn, E.J., Burn, J., DNA repair gene polymorphisms, pre-natal factors and the frequency of somatic mutations in the glycophorin-A gene among healthy newborns (2004) Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 545 (1-2), pp. 49-57. , DOI 10.1016/j.mrfmmm.2003.09.007Migliore, L., Bevilacqua, C., Scarpato, R., Cytogenetic study and FISH analysis in lymphocytes of systemic lupus erythematosus (SLE) and systemic sclerosis (SS) patients (1999) Mutagenesis, 14 (2), pp. 227-231Porciello, G., Scarpato, R., Storino, F., Cagetti, F., Marcolongo, R., Migliore, L., L'alta frequenza di micronuclei spontanei osservati nei linfociti di pazienti con sclerosi sistemica: Risultati preliminari (Italian). The high frequency of spontaneous micronuclei observed in lymphocytes of systemic sclerosis patients: preliminary results (2002) Reumatismo, 54, pp. 36-39Porciello, G., Scarpato, R., Ferri, C., Storino, F., Cagetti, F., Morozzi, G., Bellisai, F., Galeazzi, M., Spontaneous chromosome damage (micronuclei) in systemic sclerosis and Raynaud's phenomenon (2003) Journal of Rheumatology, 30 (6), pp. 1244-1247McCurdy, D., Tai, L.-Q., Frias, S., Wang, Z., Delayed repair of DNA damage by ionizing radiation in cells from patients with juvenile systemic lupus erythematosus and rheumatoid arthritis (1997) Radiation Research, 147 (1), pp. 48-54. , DOI 10.2307/3579442McConnell, J.R., Crockard, A.D., Cairns, A.P., Bell, A.L., Neutrophils from systemic lupus erythematosus patients demonstrate increased nuclear DNA damage (2002) Clinical and Experimental Rheumatology, 20 (5), pp. 653-660Derk, C.T., Associations of breast cancer development in patients with systemic sclerosis: An exploratory study (2007) Clin Rheumatol, 26, pp. 1615-1619Lipsky, P.E., Immunosuppression by D-penicillamine in vitro. Inhibition of human T lymphoctye proliferation by copper- or ceruloplasmin-dependent generation of hydrogen peroxide and protection by monocytes (1984) Journal of Clinical Investigation, 73 (1), pp. 53-65Genestier, L., Paillot, R., Fournel, S., Ferraro, C., Miossec, P., Revillard, J.-P., Immunosuppressive properties of methotrexate: Apoptosis and clonal deletion of activated peripheral T cells (1998) Journal of Clinical Investigation, 102 (2), pp. 322-328O'Donovan, P., Perrett, C.M., Zhang, X., Montaner, B., Xu, Y.-Z., Harwood, C.A., McGregor, J.M., Karran, P., Medicine: Azathioprine and UVA light generate mutagenic oxidative DNA damage (2005) Science, 309 (5742), pp. 1871-1874. , DOI 10.1126/science.1114233Sampaio-Barros, P.D., Bortoluzzo, A.B., Marangoni, R.G., Rocha, L.F., Del Rio, A.P., Samara, A.M., Survival, causes of death, and prognostic factors in systemic sclerosis: Analysis of 947 Brazilian patients (2012) J Rheumatol, 39, pp. 1971-1978Kamanli, A., Naziroglu, M., Aydilek, N., Hacievliyagil, C., Plasma lipid peroxidation and antioxidant levels in patients with rheumatoid arthritis (2004) Cell Biochemistry and Function, 22 (1), pp. 53-57. , DOI 10.1002/cbf.1055Simonini, G., Cerinic, M.M., Generini, S., Zoppi, M., Anichini, M., Cesaretti, C., Pignone, A., Cagnoni, M., Oxidative stress in systemic sclerosis (1999) Molecular and Cellular Biochemistry, 196 (1-2), pp. 85-91. , DOI 10.1023/A:1006922313774Kerr, L.D., Spiera, H., Scleroderma in association with the use of bleomycin: A report of 3 cases (1992) J Rheumatol, 19, pp. 294-296Goode, H.F., Webster, N.R., Free radicals and antioxidants in sepsis (1993) Critical Care Medicine, 21 (11), pp. 1770-1776Grob, M., Wyss, M., Spycher, M.A., Dommann, S., Schinzel, A., Burg, G., Trueb, R.M., Histopathologic and ultrastructural study of lupus-like skin lesions in a patient with Bloom syndrome (1998) Journal of Cutaneous Pathology, 25 (5), pp. 275-278. , DOI 10.1111/j.1600-0560.1998.tb01733.xMakker, S.P., Widstrom, R., Huang, J., Membranous nephropathy, interstitial nephritis, and Fanconi syndrome - Glomerular antigen (1996) Pediatric Nephrology, 10 (1), pp. 7-13. , DOI 10.1007/BF00863427Griswold, W.R., Krous, H.F., Reznik, V., Lemire, J., Wilson, N.W., Bastian, J., Spiegelberg, H., The syndrome of autoimmune interstitial nephritis and membranous nephropathy (1997) Pediatric Nephrology, 11 (6), pp. 699-702. , DOI 10.1007/s004670050369Brem, R., Fernet, M., Chapot, B., Hall, J., The methyl methanesulfonate induced S-phase delay in XRCC1-deficient cells requires ATM and ATR (2008) DNA Repair, 7, pp. 849-857Fontana, L., Bosviel, R., Delort, L., Guy, L., Chalabi, N., Kwiatkowski, F., Satih, S., Bernard-Gallon, D.J., DNA repair gene ERCC2, XPC, XRCC1, XRCC3 polymorphisms and associations with bladder cancer risk in a French cohort (2008) Anticancer Research, 28 (3 B), pp. 1853-1856Wong, R.H., Chang, S.Y., Ho, S.W., Huang, P.L., Liu, Y.J., Chen, Y.C., Polymorphisms in metabolic GSTP1 and DNA-repair XRCC1 genes with an increased risk of DNA damage in pesticide-exposed fruit growers (2008) Mutat Res, 654, pp. 168-175Eilat, D., Anderson, W.F., Structure-function correlates of autoantibodies to nucleic acids. Lessons from immunochemical, genetic and structural studies (1994) Molecular Immunology, 31 (18), pp. 1377-1390. , DOI 10.1016/0161-5890(94)90154-6Waris, G., Alam, K., Immunogenicity of superoxide radical modified-DNA: Studies on induced antibodies and SLE anti-DNA autoantibodies (2004) Life Sciences, 75 (22), pp. 2633-2642. , DOI 10.1016/j.lfs.2004.04.034, PII S002432050400654XGarg, D.K., Ali, R., Reactive oxygen species modified polyguanylic acid: Immunogenicity and implications for systemic autoimmunity (1998) Journal of Autoimmunity, 11 (4), pp. 371-378. , DOI 10.1006/jaut.1998.0208Lei, Y.-C., Hwang, S.-J., Chang, C.-C., Kuo, H.-W., Luo, J.-C., Chang, M.J.W., Cheng, T.-J., Effects on sister chromatid exchange frequency of polymorphisms in DNA repair gene XRCC1 in smokers (2002) Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 519 (1-2), pp. 93-101. , DOI 10.1016/S1383-5718(02)00127-4, PII S138357180200127

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

Background: Intravenous ferric carboxymaltose has been shown to improve symptoms and quality of life in patients with chronic heart failure and iron deficiency. We aimed to evaluate the effect of ferric carboxymaltose, compared with placebo, on outcomes in patients who were stabilised after an episode of acute heart failure. Methods: AFFIRM-AHF was a multicentre, double-blind, randomised trial done at 121 sites in Europe, South America, and Singapore. Eligible patients were aged 18 years or older, were hospitalised for acute heart failure with concomitant iron deficiency (defined as ferritin <100 μg/L, or 100–299 μg/L with transferrin saturation <20%), and had a left ventricular ejection fraction of less than 50%. Before hospital discharge, participants were randomly assigned (1:1) to receive intravenous ferric carboxymaltose or placebo for up to 24 weeks, dosed according to the extent of iron deficiency. To maintain masking of patients and study personnel, treatments were administered in black syringes by personnel not involved in any study assessments. The primary outcome was a composite of total hospitalisations for heart failure and cardiovascular death up to 52 weeks after randomisation, analysed in all patients who received at least one dose of study treatment and had at least one post-randomisation data point. Secondary outcomes were the composite of total cardiovascular hospitalisations and cardiovascular death; cardiovascular death; total heart failure hospitalisations; time to first heart failure hospitalisation or cardiovascular death; and days lost due to heart failure hospitalisations or cardiovascular death, all evaluated up to 52 weeks after randomisation. Safety was assessed in all patients for whom study treatment was started. A pre-COVID-19 sensitivity analysis on the primary and secondary outcomes was prespecified. This study is registered with ClinicalTrials.gov, NCT02937454, and has now been completed. Findings: Between March 21, 2017, and July 30, 2019, 1525 patients were screened, of whom 1132 patients were randomly assigned to study groups. Study treatment was started in 1110 patients, and 1108 (558 in the carboxymaltose group and 550 in the placebo group) had at least one post-randomisation value. 293 primary events (57·2 per 100 patient-years) occurred in the ferric carboxymaltose group and 372 (72·5 per 100 patient-years) occurred in the placebo group (rate ratio [RR] 0·79, 95% CI 0·62–1·01, p=0·059). 370 total cardiovascular hospitalisations and cardiovascular deaths occurred in the ferric carboxymaltose group and 451 occurred in the placebo group (RR 0·80, 95% CI 0·64–1·00, p=0·050). There was no difference in cardiovascular death between the two groups (77 [14%] of 558 in the ferric carboxymaltose group vs 78 [14%] in the placebo group; hazard ratio [HR] 0·96, 95% CI 0·70–1·32, p=0·81). 217 total heart failure hospitalisations occurred in the ferric carboxymaltose group and 294 occurred in the placebo group (RR 0·74; 95% CI 0·58–0·94, p=0·013). The composite of first heart failure hospitalisation or cardiovascular death occurred in 181 (32%) patients in the ferric carboxymaltose group and 209 (38%) in the placebo group (HR 0·80, 95% CI 0·66–0·98, p=0·030). Fewer days were lost due to heart failure hospitalisations and cardiovascular death for patients assigned to ferric carboxymaltose compared with placebo (369 days per 100 patient-years vs 548 days per 100 patient-years; RR 0·67, 95% CI 0·47–0·97, p=0·035). Serious adverse events occurred in 250 (45%) of 559 patients in the ferric carboxymaltose group and 282 (51%) of 551 patients in the placebo group. Interpretation: In patients with iron deficiency, a left ventricular ejection fraction of less than 50%, and who were stabilised after an episode of acute heart failure, treatment with ferric carboxymaltose was safe and reduced the risk of heart failure hospitalisations, with no apparent effect on the risk of cardiovascular death. Funding: Vifor Pharma. © 2020 Elsevier Lt

Antiinflammatory therapy with canakinumab for atherosclerotic disease

BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. METHODS: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P=0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P=0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P=0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P=0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P=0.31). CONCLUSIONS: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. Copyright © 2017 Massachusetts Medical Society